An observational study in Non-Squamous Non-Small Cell Lung Cancer, sponsored by Hoffmann-La Roche. Completed at 88 sites in France. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2018-05-14.
Sponsored by Hoffmann-La Roche · Observational
This prospective, observational study will assess the effectiveness and safety of Avastin (bevacizumab) as 1st line therapy in elderly patients with advanced non-squamous non-small cell lung cancer in clinical practice. Therapy with Avastin and standard chemotherapy will be administered according to the treating physician. Data will be collected for approximately 4 years.
7,243 studies on the registry are indexed under Lung Neoplasms; 1,557 are open to participants now.
This study's enrollment of 279 is above the median of 189 across 1,514 observational studies indexed under Lung Neoplasms.
Browse Lung Neoplasms studies →Hoffmann-La Roche is the lead sponsor of 2,061 studies on the registry; 85 are open to participants now.
Of its 319 completed or terminated interventional studies of FDA-regulated products, 239 (75%) have results posted.
Counted across the registry records on this site, refreshed daily.
Patients aged over 65 years with non-squamous non-small cell lung cancer
Exclusion Criteria:
Proportion of patients treated with a chemotherapy in combination with Avastin including description of chemotherapy regimens and management of Avastin treatment
Time frame: Approximately 4 years
Characteristics of patients with advanced non-squamous non-small cell lung cancer
Time frame: Approximately 4 years
Tumor characteristics of patients with advanced non-squamous non-small cell lung cancer
Time frame: Approximately 4 years
Progression-free survival
Time frame: Approximately 4 years
Overall survival
Time frame: Approximately 4 years
Quality of Life
Time frame: Approximately 4 years
Safety: Incidence of adverse events
Time frame: Approximately 4 years
Reasons of non-use of Avastin as first-line therapy
Time frame: Approximately 4 years
This study is completed, as verified in May 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hoffmann-La Roche